Literature DB >> 25685295

Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Yuri Tolkach1, Florian Imkamp1, Konstantin Godin2, Hendrik Van Poppel3.   

Abstract

Substantial efforts are being made in research on the molecular genetic characterization of prostate cancer. The number of fundamental research programs in prostate cancer molecular biology and genetics is overwhelming. However, a significant gap appears to exist between the huge number of studies on the genetic characterization of prostate cancer, which often have limited translation into clinical practice or simply were not conceived to be so translated, and clinical practice. From a clinical point of view, this balance should be urgently shifted towards rapid translation into urological practice. However, prostate cancer is characterized by prominent genetic heterogeneity, which could be a very difficult barrier to overcome. In this review, we discuss the possible clinical applications of scientific data from fundamental studies of prostate cancer genetics, the main problems with the translation of these data to clinics, and future perspectives.

Entities:  

Keywords:  Biological markers; Molecular biology; Prostate neoplasms; Translations

Mesh:

Substances:

Year:  2015        PMID: 25685295      PMCID: PMC4325124          DOI: 10.4111/kju.2015.56.2.90

Source DB:  PubMed          Journal:  Korean J Urol        ISSN: 2005-6737


  76 in total

1.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

Review 2.  Epigenetic biomarkers in prostate cancer: Current and future uses.

Authors:  Karen Chiam; Carmela Ricciardelli; Tina Bianco-Miotto
Journal:  Cancer Lett       Date:  2012-03-03       Impact factor: 8.679

3.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

4.  Molecular classification of prostate cancer using curated expression signatures.

Authors:  Elke K Markert; Hideaki Mizuno; Alexei Vazquez; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

5.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.

Authors:  Jacques Lapointe; Chunde Li; Craig P Giacomini; Keyan Salari; Stephanie Huang; Pei Wang; Michelle Ferrari; Tina Hernandez-Boussard; James D Brooks; Jonathan R Pollack
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

6.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

7.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Authors:  Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

8.  Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.

Authors:  Katharina Grupp; Sebastian Kohl; Hüseyin Sirma; Ronald Simon; Stefan Steurer; Andreas Becker; Meike Adam; Jakob Izbicki; Guido Sauter; Sarah Minner; Thorsten Schlomm; Maria Christina Tsourlakis
Journal:  Mod Pathol       Date:  2012-11-30       Impact factor: 7.842

9.  Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Authors:  Nicholas Erho; Anamaria Crisan; Ismael A Vergara; Anirban P Mitra; Mercedeh Ghadessi; Christine Buerki; Eric J Bergstralh; Thomas Kollmeyer; Stephanie Fink; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Karla V Ballman; Timothy J Triche; Peter C Black; R Jeffrey Karnes; George Klee; Elai Davicioni; Robert B Jenkins
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

10.  Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Authors:  B Gumuskaya; B Gurel; H Fedor; H-L Tan; C A Weier; J L Hicks; M C Haffner; T L Lotan; A M De Marzo
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-04-02       Impact factor: 5.554

View more
  1 in total

Review 1.  Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review.

Authors:  Zhaoyi Chen; Travis Gerke; Victoria Bird; Mattia Prosperi
Journal:  Biomed Hub       Date:  2017-05-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.